Phase 2 Trial of AGEN2034 (anti-PD-1) as a | Clinical Research Studies Listing

Phase 2 Trial of AGEN2034 (anti-PD-1) as a Monotherapy of Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

Recruiting

99 years or below

All

Phase 2

6 participants needed

1 Location

Brief description of study

The research study is being conducted to study the PD-1 antibody, AGEN2034 alone, or in combination with the CTLA-4 antibody, AGEN1884, in women with recurrent cervical cancer. Subjects will be asked to complete the following research procedures: 12 lead electrocardiogram (ECG) and evaluation of heart function (to determine heart health). Routine blood tests for health and safety reasons (about 1 tablespoon) to measure how many white blood cells, red blood cells, and platelets you have, the function of your liver, kidneys, thyroid and to measure the ability of your blood to clot. Urinalysis. Serum pregnancy test (if you are a woman of childbearing potential). Tumor Imaging Computed Tomography (CT) scan (not required if performed within 21 days prior to the first dose of trial treatment). Collection of stored tumor specimen from previous biopsy to test for PD-L1 expression later. If stored tumor specimen is not available, a fresh biopsy will be required.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: cervical cancer
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 834169

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Phase 2 Trial of AGEN2034 (anti-PD-1) as a Monotherapy of Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

Brief description of study

Eligibility of study

Find a site

Interested in the study